JP7611813B2 - 超高速凍結による表面改質された治療活性粒子の組成物 - Google Patents

超高速凍結による表面改質された治療活性粒子の組成物 Download PDF

Info

Publication number
JP7611813B2
JP7611813B2 JP2021503813A JP2021503813A JP7611813B2 JP 7611813 B2 JP7611813 B2 JP 7611813B2 JP 2021503813 A JP2021503813 A JP 2021503813A JP 2021503813 A JP2021503813 A JP 2021503813A JP 7611813 B2 JP7611813 B2 JP 7611813B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
tff
excipient
voriconazole
inhaler
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021503813A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530551A (ja
JP2021530551A5 (https=
JPWO2020023614A5 (https=
Inventor
サード ロバート オー． ウィリアムズ
チェホ ムーン
アラン ビー． ワッツ
ジョン ジェイ． コレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2021530551A publication Critical patent/JP2021530551A/ja
Publication of JP2021530551A5 publication Critical patent/JP2021530551A5/ja
Publication of JPWO2020023614A5 publication Critical patent/JPWO2020023614A5/ja
Priority to JP2024154560A priority Critical patent/JP2024170583A/ja
Application granted granted Critical
Publication of JP7611813B2 publication Critical patent/JP7611813B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021503813A 2018-07-24 2019-07-24 超高速凍結による表面改質された治療活性粒子の組成物 Active JP7611813B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024154560A JP2024170583A (ja) 2018-07-24 2024-09-09 超高速凍結による表面改質された治療活性粒子の組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862702674P 2018-07-24 2018-07-24
US62/702,674 2018-07-24
PCT/US2019/043202 WO2020023614A1 (en) 2018-07-24 2019-07-24 Compositions of surface-modified therapeutically active particles by ultra-rapid freezing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024154560A Division JP2024170583A (ja) 2018-07-24 2024-09-09 超高速凍結による表面改質された治療活性粒子の組成物

Publications (4)

Publication Number Publication Date
JP2021530551A JP2021530551A (ja) 2021-11-11
JP2021530551A5 JP2021530551A5 (https=) 2022-08-01
JPWO2020023614A5 JPWO2020023614A5 (https=) 2022-08-01
JP7611813B2 true JP7611813B2 (ja) 2025-01-10

Family

ID=69181152

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021503813A Active JP7611813B2 (ja) 2018-07-24 2019-07-24 超高速凍結による表面改質された治療活性粒子の組成物
JP2024154560A Pending JP2024170583A (ja) 2018-07-24 2024-09-09 超高速凍結による表面改質された治療活性粒子の組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024154560A Pending JP2024170583A (ja) 2018-07-24 2024-09-09 超高速凍結による表面改質された治療活性粒子の組成物

Country Status (12)

Country Link
US (1) US20210338671A1 (https=)
EP (1) EP3827260A4 (https=)
JP (2) JP7611813B2 (https=)
KR (1) KR20210038583A (https=)
CN (1) CN112673257B (https=)
AU (1) AU2019311086A1 (https=)
BR (1) BR112021001290A2 (https=)
CA (1) CA3106618A1 (https=)
EA (1) EA202190331A1 (https=)
IL (1) IL280342A (https=)
MX (1) MX2021000796A (https=)
WO (1) WO2020023614A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014186754A2 (en) 2013-05-16 2014-11-20 Board Of Regents The University Of Texas System Dry solid aluminum adjuvant-containing vaccines and related methods thereof
US11918646B2 (en) 2017-12-11 2024-03-05 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
CN113398079B (zh) * 2020-03-16 2024-01-19 鲁南制药集团股份有限公司 一种注射用氟达拉滨冻干粉
BR112023001929A2 (pt) 2020-09-03 2023-03-14 Philip Morris Products Sa Composições em pó ativas de baixa higroscopicidade
US20230301919A1 (en) * 2020-09-03 2023-09-28 Philip Morris Products S.A. Freeze dried low hygroscopicity active powder compositions
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
CN117241786A (zh) * 2021-03-12 2023-12-15 德克萨斯大学系统董事会 使用基于悬浮液的薄膜冷冻制备干燥粉末的方法
US12015755B2 (en) 2021-03-25 2024-06-18 Korea Advanced Institute Of Science And Technology Real-time omnidirectional stereo matching method using multi-view fisheye lenses and system thereof
CN113484469B (zh) * 2021-06-30 2022-11-18 中国科学院青海盐湖研究所 水合盐体系相变储能材料纳米尺度相分离的原位表征方法
CN116440084A (zh) * 2022-01-07 2023-07-18 浙江萃泽医药科技有限公司 一种可吸入的药物粉末制剂及其制备方法
AU2023366929A1 (en) 2022-10-25 2025-05-08 Veradermics, Incorporated Compositions and methods of use for modified release minoxidil

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008518007A (ja) 2004-10-29 2008-05-29 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 肺感染症の処置のための粒子
JP2009514902A (ja) 2005-11-11 2009-04-09 バイオラブ・サヌス・ファーマセウティカ・エルティーディーエー． 凝集ナノ粒子を含む固体医薬組成物及びその生成方法
JP2018514569A (ja) 2015-05-01 2018-06-07 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 多剤脆性マトリックス組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08310969A (ja) * 1995-05-22 1996-11-26 Lion Corp 固形薬品組成物及びその製造方法
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
CN1750811A (zh) * 2001-10-19 2006-03-22 巴克斯特国际公司 在冷冻水基质中包括颗粒的稳定组合物
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
US9061027B2 (en) * 2004-08-27 2015-06-23 Board Of Regents, The University Of Texas System Enhanced delivery of drug compositions to treat life threatening infections
US8361439B1 (en) * 2005-01-04 2013-01-29 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
WO2011046842A1 (en) * 2009-10-12 2011-04-21 The Regents Of The University Of California Targeted nanoclusters and methods of their use
US10973763B2 (en) * 2011-06-17 2021-04-13 Berg Llc Inhalable pharmaceutical compositions
US9801855B2 (en) * 2012-03-07 2017-10-31 National Institute Of Pharmaceutical Education And Research (Niper) Nanocrystalline solid dispersion compositions and process of preparation thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008518007A (ja) 2004-10-29 2008-05-29 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 肺感染症の処置のための粒子
JP2009514902A (ja) 2005-11-11 2009-04-09 バイオラブ・サヌス・ファーマセウティカ・エルティーディーエー． 凝集ナノ粒子を含む固体医薬組成物及びその生成方法
JP2018514569A (ja) 2015-05-01 2018-06-07 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 多剤脆性マトリックス組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Advanced Drug Delivery Reviews，2015年，Vol.85，pp.83-99
International Journal of Pharmaceutics，2012年，Vol.429，pp.46-57

Also Published As

Publication number Publication date
EA202190331A1 (ru) 2021-06-17
JP2021530551A (ja) 2021-11-11
BR112021001290A2 (pt) 2021-04-27
CA3106618A1 (en) 2020-01-30
CN112673257A (zh) 2021-04-16
JP2024170583A (ja) 2024-12-10
MX2021000796A (es) 2021-06-15
US20210338671A1 (en) 2021-11-04
AU2019311086A1 (en) 2021-02-04
CN112673257B (zh) 2025-02-25
KR20210038583A (ko) 2021-04-07
WO2020023614A1 (en) 2020-01-30
IL280342A (en) 2021-03-25
EP3827260A1 (en) 2021-06-02
EP3827260A4 (en) 2022-05-04

Similar Documents

Publication Publication Date Title
JP7611813B2 (ja) 超高速凍結による表面改質された治療活性粒子の組成物
RU2629333C2 (ru) Сухие порошковые композиции в виде частиц, которые содержат два или более активных ингредиента, для лечения обструктивных или воспалительных заболеваний дыхательных путей
Duret et al. Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties
ES2814336T3 (es) Partículas de agregado
ES2953878T3 (es) Composición que comprende al menos dos polvos secos obtenidos mediante secado por aspersión para aumentar la estabilidad de la formulación
JP2003533449A (ja) ドラッグ・デリバリー用の安定な金属イオン−脂質粉末状医薬組成物とその利用方法
JP2023520018A (ja) ニクロサミドの薬学的組成物
JP6940416B2 (ja) 多剤脆性マトリックス組成物
CA2898700C (en) Deamorphization of spray-dried formulations via spray-blending
KR20100099281A (ko) 유기 화합물
EP3030224B1 (en) Inhalable particles comprising tiotropium and indacaterol
Liu et al. Formulation of a novel fixed dose combination of salmeterol xinafoate and mometasone furoate for inhaled drug delivery
US20220313611A1 (en) Methods to prepare dry powders using suspension based thin film freezing
Surasarang et al. Pharmaceutical cryogenic technologies
HK40050243A (en) Compositions of surface-modified therapeutically active particles by ultra-rapid freezing
WO2024026412A1 (en) Thin film freezing methods and compositions formulated from dispersed active agents
WO2024151838A1 (en) Co-crystals with thin-film freeze-drying process to enhance delivery
Moon et al. Thin-Film Freeze-Drying Process for Versatile Particles for Inhalation Drug Delivery
US20250387326A1 (en) Crystalline pharmaceutical composition for inhalation comprising sugar and lipid composite particles and process for manufacture

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220722

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230816

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240215

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240926

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241018

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241224

R150 Certificate of patent or registration of utility model

Ref document number: 7611813

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150